Explore the words cloud of the VIRION project. It provides you a very rough idea of what is the project "VIRION" about.
The following table provides information about the project.
Coordinator |
STICHTING VUMC
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Project website | http://www.virion-consortium.eu |
Total cost | 1˙304˙413 € |
EC max contribution | 1˙304˙413 € (100%) |
Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
Code Call | H2020-MSCA-ITN-2014 |
Funding Scheme | MSCA-ITN-EID |
Starting year | 2015 |
Duration (year-month-day) | from 2015-10-01 to 2019-09-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | STICHTING VUMC | NL (AMSTERDAM) | coordinator | 510˙748.00 |
2 | TILT BIOTHERAPEUTICS OY | FI (HELSINKI) | participant | 538˙290.00 |
3 | ORCA Therapeutics BV | NL (Nijmegen) | participant | 255˙374.00 |
4 | STICHTING VU | NL (AMSTERDAM) | participant | 0.00 |
5 | Adiutide Pharmaceuticals GmbH | DE (Glashuetten) | partner | 0.00 |
6 | Diamond Biopharm Limited | UK (Sawbridgeworth) | partner | 0.00 |
7 | Hyphen Projects BV | NL (Hilversum) | partner | 0.00 |
8 | Netherlands society of gene and cell therapy | NL (Amsterdam) | partner | 0.00 |
9 | Quintess Consultancy BV | NL (Schiedam) | partner | 0.00 |
The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques.
Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses.
However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.
Doctorate | Other | 2020-01-14 16:23:20 |
Presentation | Other | 2019-10-15 13:18:34 |
Supervisory board of the network | Other | 2019-06-12 11:55:37 |
Recruitment | Other | 2019-06-12 11:55:37 |
Public website | Websites, patent fillings, videos etc. | 2019-06-12 11:55:37 |
Communication | Websites, patent fillings, videos etc. | 2019-06-12 11:55:37 |
Take a look to the deliverables list in detail: detailed list of VIRION deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2016 |
Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri Tähtinen, VÃctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus Vähä-Koskela, Anna Kanerva, Akseli Hemminki Corrigendum to “Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma†published pages: 2033, ISSN: 1525-0016, DOI: 10.1038/mt.2016.196 |
Molecular Therapy 24/11 | 2019-10-29 |
2018 |
Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero, Dave Lumen, Mikko Siurala, Anu J. Airaksinen, Victor Cervera-Carrascon, Siri Tähtinen, Anna Kanerva, Akseli Hemminki Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus published pages: 109-121, ISSN: 2372-7705, DOI: 10.1016/j.omto.2018.10.005 |
Molecular Therapy - Oncolytics 11 | 2019-10-29 |
2018 |
Tereza Brachtlova, Victor van Beusechem Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens published pages: 228, ISSN: 2073-4409, DOI: 10.3390/cells7120228 |
Cells 7/12 | 2019-10-29 |
2019 |
Camilla Heiniö, Suvi Sorsa, Mikko Siurala, Susanna Grönberg-Vähä-Koskela, Riikka Havunen, Elina Haavisto, Anniina Koski, Otto Hemminki, Sadia Zafar, VÃctor Cervera-Carrascon, Eleonora Munaro, Anna Kanerva, Akseli Hemminki Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs published pages: 740-752, ISSN: 1043-0342, DOI: 10.1089/hum.2018.240 |
Human Gene Therapy 30/6 | 2019-10-29 |
2016 |
Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri Tähtinen, VÃctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus Vähä-Koskela, Anna Kanerva, Akseli Hemminki Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma published pages: 1435-1443, ISSN: 1525-0016, DOI: 10.1038/mt.2016.137 |
Molecular Therapy 24/8 | 2019-10-29 |
2019 |
Victor Cervera-Carrascon, Riikka Havunen, Akseli Hemminki Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. published pages: 443-455, ISSN: 1471-2598, DOI: 10.1080/14712598.2019.1595582 |
Expert Opinion on Biological Therapy 19/5 | 2019-10-29 |
2017 |
Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna Grönberg-Vähä-Koskela, Michael Behr, Siri Tähtinen, João Manuel Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva, Akseli Hemminki Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy published pages: 77-86, ISSN: 2372-7705, DOI: 10.1016/j.omto.2016.12.004 |
Molecular Therapy - Oncolytics 4 | 2019-10-29 |
2018 |
Sadia Zafar, Suvi Sorsa, Mikko Siurala, Otto Hemminki, Riikka Havunen, Victor Cervera-Carrascon, João Manuel Santos, Hongjie Wang, Andre Lieber, Tanja De Gruijl, Anna Kanerva, Akseli Hemminki CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy published pages: e1490856, ISSN: 2162-402X, DOI: 10.1080/2162402x.2018.1490856 |
OncoImmunology 7/10 | 2019-10-29 |
2018 |
João Manuel Santos, VÃctor Cervera-Carrascon, Riikka Havunen, Sadia Zafar, Mikko Siurala, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy published pages: 2243-2254, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.06.001 |
Molecular Therapy 26/9 | 2019-10-29 |
2017 |
Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma published pages: e1319028, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1319028 |
OncoImmunology 6/9 | 2019-10-29 |
2018 |
V. Cervera-Carrascon, M. Siurala, J. M. Santos, R. Havunen, S. Tähtinen, P. Karell, S. Sorsa, A. Kanerva, A. Hemminki TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade published pages: e1412902, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1412902 |
OncoImmunology 7/5 | 2019-10-29 |
2017 |
Joao Manuel Santos, Riikka Havunen, Mikko Siurala, VÃctor Cervera-Carrascon, Siri Tähtinen, Suvi Sorsa, Marjukka Anttila, Pauliina Karell, Anna Kanerva, Akseli Hemminki Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy published pages: 1458-1468, ISSN: 0020-7136, DOI: 10.1002/ijc.30839 |
International Journal of Cancer 141/7 | 2019-06-12 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIRION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VIRION" are provided by the European Opendata Portal: CORDIS opendata.